Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITGA6-Targeting Fluorescence Imaging in HCC Surgery
NCT06204835Phase 1Recruiting
- Sponsor
- Institute of Automation, Chinese Academy of Sciences
- Start
- Jan 2024
- Primary completion
- Dec 2034
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD-Cy7 in hepatocellular carcinoma (HCC), sponsored by Institute of Automation, Chinese Academy of Sciences. Primary endpoint: Detection of Hepatocellular Carcinoma Lesions. Started Jan 2024; status: recruiting.
02
Drugs
RD-Cy7
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06204835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204835.